Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate: The vaccine is the first to be tested in the United States to generate late-stage data. The companies said an early analysis of the results showed that individuals who received two injections of the vaccine three weeks apart experienced more than 90% fewer cases of symptomatic Covid-19 than those who received a placebo.
Universal masking of health care workers (HCWs) and patients can significantly reduce transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, expert says.
COVID-19 and Ventilation: Airborne transmission and aerosols could pose a risk in indoor settings. Beside masks and social distancing, “air ventilation” is also very important to reduce the risk of COVID-19.
Wearing masks could help avoid major illness even if you get coronavirus, experts say.
China to Supply Coronavirus Vaccine to Pakistan: According to a report published in The Wall Street Journal Pakistan will receive enough doses early in distribution to vaccinate the most vulnerable among its population, including the elderly, health-care workers and people with medical conditions associated with serious cases of Covid-19. About one-fifth of the country’s population could be covered by the allocation.
The Lancet: The chance of transmission through inanimate surfaces is very small. Periodically disinfecting surfaces and use of gloves are reasonable precautions to stay safe from this virus.
Coronavirus: Encouraging early results from clinical trials have raised hopes for an effective Coronavirus vaccine.
WHO links smoking with increased risk for COVID-19 severity. A scientific brief released on June 30th, 2020
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses. These results, together with the induction of both humoral and cellular immune responses, support large scale evaluation of this candidate vaccine in an ongoing phase 3 programme.
In a recent interview Dr. Rhonda Pattrick, an American biomedical scientist and nutritional researcher, addressed the possible role of Vitamin D to prevent COVID-19 severity.
Coronavirus: Experts estimate that only 1000 Covid-19 viral particles are needed to make a person infected.
Vitamin D supplementation helps to prevent respiratory tract infections: a systematic review and meta-analysis of British Medical Journal.
The infectiousness of patients with COVID-19 during their incubation periods is high and could substantially increase the difficulty of curbing the ongoing pandemic: a retrospective cohort study.
In a recent interview, Dr. Rhonda Pattrick, an american biomedical scientist and nutritional researcher sheds light on the possible role of vitamin D in reducing the severity of COVID-19.
Gilead to start trials of an inhaled version of remdesivir: In an open letter Gilead’s Chairman and CEO, Daniel O’Day, announced that they have received approval from the FDA to start the clinical trials. They hope to begin studies in patients with COVID-19 in August.
Coronavirus: SARS-CoV-2 infection induced protective immunity against re-exposure in nonhuman primates.
Coronavirus: Covid-19 patients are no longer infectious 11 days after getting sick, research shows. Experts believe the findings can significantly cut down the time patients spend in hospitals and care facilities.
Coronavirus: Ibuprofen tested as a treatment. Scientists are running a trial to see if ibuprofen can help hospital patients suffering with COVID-19.
Moderna’s coronavirus vaccine shows encouraging early results: The data released Monday by Moderna is encouraging, but represents only a first step in a long process to bring a vaccine to market.
F.D.A Clears First Home Saliva Test for Coronavirus: The Food and Drug Administration is permitting a Rutgers lab to start selling spit-collection kits to detect the coronavirus.
Scientists to Stop COVID-19: A group of citizen-scientists offers four actionable, non-partisan proposals to produce safe and effective COVID-19 therapeutics and vaccines in the shortest possible timeframe, and to reopen society in a manner that reduces the risk of future COVID-19 outbreaks.
Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark: Roche will provide high double-digit millions of tests already in May for countries accepting the CE mark and in the U.S. under Emergency Use Authorization, further ramping up capacities thereafter.
New York clinical trial quietly tests heartburn remedy against coronavirus: The fast-growing list of possible treatments for the novel coronavirus includes an unlikely candidate: famotidine, the active compound in the over-the-counter heartburn drug Pepcid.
New data on Gilead’s remdesivir, released by accident, show no benefit for coronavirus patients. Company still sees reason for hope: The antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients with Covid-19 or prevent them from dying, according to results from a long-awaited clinical trial conducted in China.
COVID-19 vaccine protects monkeys from new coronavirus, Chinese biotech reports: For the first time, one of the many COVID-19 vaccines in development has protected an animal, rhesus macaques, from infection by the new coronavirus, scientists report.
Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment: A Chicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week.
China Approves Two Experimental Coronavirus Vaccines to Enter Clinical Trials: China has approved early-stage human tests for two experimental vaccines to combat the new coronavirus.
Gilead’s Drug Remdesivir Shows Hope In Treating Coronavirus Patients, But Data Is Limited: Gilead Sciences announced Friday that in a small study of remdesivir in severely ill COVID-19 patients, the majority saw symptom improvement when treated with the drug.
Gilead turbocharges production of COVID-19 hopeful remdesivir: Gilead Sciences' remdesivir has courted high hopes as a potential treatment for COVID-19.
FDA approves first antibody test in the US to detect coronavirus: Widespread antibody testing can be useful in determining how many people in a population were infected with the virus and might now be immune.
Nations with Mandatory TB Vaccines Show Fewer Coronavirus Deaths: New study finds a correlation, but clinical trials are still in progress.
Bill Gates: Here’s how to make up for lost time on covid-19.
How Hospitals Are Using AI to Battle Covid-19: While we race to dampen the virus’s spread, we can optimize our response mechanisms, digitizing as many steps as possible.
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma: In this uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by an improvement in clinical status.
COVID-19 Vaccine Candidate Shows Promise: University of Pittsburgh School of Medicine scientists today announced a potential vaccine against SARS-CoV-2, the new coronavirus causing the COVID-19 pandemic.
Abbott Launches Molecular Point-of-care Test To Detect Novel Coronavirus In As Little As Five Minutes: Abbott announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19).
Top COVID-19 aspirants chloroquine, AbbVie's Kaletra and a flu drug disappoint in clinical tests: Malaria drug chloroquine, AbbVie’s HIV combo therapy Kaletra and an influenza med called Arbidol are among top candidates that physicians are repurposing for the treatment of COVID-19.
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.